These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31770546)

  • 1. A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?
    Cross JH; Cock H
    Neuropharmacology; 2020 Jun; 170():107861. PubMed ID: 31770546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids in treatment-resistant epilepsy: A review.
    O'Connell BK; Gloss D; Devinsky O
    Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational cannabinoids in seizure disorders, what have we learned thus far?
    Ružić Zečević D; Folić M; Tantoush Z; Radovanović M; Babić G; Janković SM
    Expert Opin Investig Drugs; 2018 Jun; 27(6):535-541. PubMed ID: 29842819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse effects of cannabinoids.
    Anciones C; Gil-Nagel A
    Epileptic Disord; 2020 Jan; 22(S1):29-32. PubMed ID: 31941644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and drug interactions of cannabinoids.
    Landmark CJ; Brandl U
    Epileptic Disord; 2020 Jan; 22(S1):16-22. PubMed ID: 31941642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
    Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
    Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders.
    Golub V; Reddy DS
    Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie MJ; Ben-Menachem E
    Epilepsia; 2018 Feb; 59(2):291-296. PubMed ID: 29214639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
    Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
    Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
    Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
    Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.